BeOne Medicines (NASDAQ: ONC) director granted 18,980 restricted share units

Rhea-AI Filing Summary

BRANDICOURT OLIVIER reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. director Olivier Brandicourt received a grant of 18,980 Ordinary Shares in the form of restricted share units on June 11, 2026 at no cash cost, as director compensation. These restricted share units vest in full on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Brandicourt directly holds 46,306 Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BRANDICOURT OLIVIER

Role null

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,980	$0.00	--

Holdings After Transaction: Ordinary Shares — 46,306 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 18,980 shares Post-transaction holdings: 46,306 shares Grant price: $0.0000 per share

3 metrics

RSU grant size 18,980 shares Restricted share units granted on June 11, 2026

Post-transaction holdings 46,306 shares Ordinary Shares directly held after the grant

Grant price $0.0000 per share Reported transaction price for RSU award

Key Terms

restricted share units, annual general meeting, accelerated vesting, Independent Non-Executive Director Compensation Policy

4 terms

restricted share units financial

"Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur..."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

annual general meeting regulatory

"shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting"

accelerated vesting financial

"unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy"

Independent Non-Executive Director Compensation Policy financial

"triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRANDICOURT OLIVIER

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		18,980	A	$0	46,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BeOne Medicines (ONC) director Olivier Brandicourt report in this Form 4?

Olivier Brandicourt reported receiving 18,980 Ordinary Shares as a restricted share unit award. The grant is part of his director compensation and was issued at no cash cost, increasing his direct holdings to 46,306 shares after the transaction.

How many BeOne Medicines (ONC) shares does Olivier Brandicourt hold after this grant?

After the June 11, 2026 restricted share unit award, Olivier Brandicourt directly holds 46,306 Ordinary Shares of BeOne Medicines. This figure includes the newly granted 18,980 restricted share units that were added to his existing position as disclosed in the Form 4.

Was the BeOne Medicines (ONC) Form 4 transaction an open-market purchase or a grant?

The Form 4 shows a grant or award acquisition, not an open-market purchase. Brandicourt received 18,980 restricted share units at a reported price of $0.0000 per share as part of director compensation, rather than buying shares on the open market.

When do Olivier Brandicourt’s BeOne Medicines (ONC) restricted share units vest?

The restricted share units become fully vested on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual general meeting. Vesting continues only while he serves as a director, subject to potential accelerated vesting under company policy.

What conditions could stop vesting of BeOne Medicines (ONC) restricted share units granted to Olivier Brandicourt?

All vesting stops if Brandicourt resigns from the board or otherwise ceases to serve as a director. The only exception is if a triggering event for accelerated vesting occurs under the company’s Independent Non-Executive Director Compensation Policy.